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Vitamin D Metabolism in Health and Disease
Norman H. Bell, MD'

1,25-Dihydroxyvitamin D3 Receptor Structure
and Function

I

n this portion ofthe program the most recent information conceming factors that regulate the production and biologic action of 1,25-dihydroxyvitamin D, the most active metabolite of
vitamin D, in normal and disease states was presented. Haussler
(1) described the stmcture and functional domains of the receptor for 1,25-dihydroxyvitamin D. The human receptor is a polypeptide containing 427 amino acids with an N-terminal DNA
binding domain (150 amino acids) and a C-terminal hormone
binding domain (226 amino acids) that are separated by a
"hinge" (51 amino acids). The DNA binding region contains
two "zincfingers"that are thought to be important in binding of
the 1,25-dihydroxyvitamin D-receptor complex to DNA (see
below). The vitamin D receptor bears a striking resemblance to
other nonpolypeptide hormonal receptors including the
glucocorticoid receptor, estrogen receptor, retinoic acid receptor, and thyroid receptor (1). Not surprising is the finding that
there is a high degree of homology among the receptors at the
DNA binding site. Haussler indicated that 1,25-dihydroxyvitamin D3 upregulates its receptor, that phosphorylation may
occur in this process, and that upregulation may be physiologically important by amplifying gene regulation and biologic action. Although the mechanisms by which 1,25-dihydroxyvitamin D regulates gene expression are not known,
Haussler proposed a model in which phosphorylation of the vitamin D receptor is catalyzed by casein kinase and the hormonereceptor-DNA complex initiates transcription (1).

Hereditary Resistance to 1,25-Dihydroxyvitamin
D: Pathophysiology, Diagnosis, and IVeatment
Liberman and Marx (2) indicated that five defects in hereditary vitamin D-dependent rickets, type I I , have been described
based on studies of cellular uptake and nuclear binding of
^H-1,25-dihydroxyvitamin D,. These are outiined as follows:
Type I; no binding of hormone to soluble cell extract or
nuclei.
Type II: reduced binding capacity with normal binding affinity to soluble cell extract and nuclei (reduced number of
receptors).
Type III: reduced binding affinity with normal binding capacity (normal number of receptors).
Type IV: normal binding affinity and capacity to soluble cell
extract and no nuclear uptake.
Type V: near-normal binding affinity and capacity to soluble
cell extract and abnormal elution of hormone-receptor complex
from heterologous DNA-cellulose.
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Type VI was not described but would include patients with
posttranscription defects who should show normal binding and
nuclear uptake of 1,25-dihydroxyvitamin D3 and normal elution
of hormone-receptor complex from heterologous DNA-cellulose. Patients with types III and IV disease respond to large
doses of 1,25-dihydroxyvitamin D3, whereas patients with types
I , II, and V disease respond poorly or not at all.
Based on thesefindingsand assuming that receptor defects
are qualitative (and result from point mutations) and not quantitative (and do not result from lack of expression), it can be predicted that the stmcture of the 1,25-dihydroxyvitamin D-binding domain of the receptor is abnormal in patients with type I
disease and that stmcture of the DNA binding domain is abnormal in patients with type V disease. It is now known that two
separate mutations exist in type V disease. Point mutations have
been identified in each of the two "zincfingers"which account
for the lack of response to 1,25-dihydroxyvitamin D3 in vivo and
abnormal nuclear uptake of the 1,25-dihydroxyvitamin D3-receptor complex in vitro in two different families with vitamin Ddependentrickets,type II (Pike JW, personal communication).
These results emphasize the importance of the stmcture of the
cysteine-containing loops or "zinc fingers" in binding of
the 1,25-dihydroxyvitamin D3-receptor complex for biologic
function ofthe vitamin. Studies are in progress in Dr. Pike's laboratory to determine whether abnormal structure of the
1,25-dihydroxyvitamin D-binding domain of the receptor or
abnormalities in posttranscription events are responsible for expression of the disease in other patients. He proposes to transfect
cells that have an abnormal receptor with the gene for the normal
vitamin D receptor to determine whether a defective receptor
fully accounts for the disease in a given patient.

The Role of Phosphorus in Modulating Vitamin D
Metabolism in Health and Disease
Previous studies in rats showed the importance of dietary
phosphate in regulating the production of 1,25-dihydroxyvitamin D (3). Thus, phosphate intake varied directly with renal
production ofthe metabolite. Also, previous studies demonstrated the importance of restriction of phosphate intake in preventing secondary hyperparathyroidism in chronic renal failure
(4). Morris et al (5) showed that changes in phosphate intake regulate the renal production of 1,25-dihydroxyvitamin D and
semm 1,25-dihydroxyvitamin D in nonnal subjects. They also
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showed that phosphate restriction prevents inhibition of the renal
synthesis of 1,25-dihydroxyvitamin D and secondary hyperparathyroidism even in patients with modest reductions in
glomemlar filtration rate. Their studies indicate, therefore, that
dietary intake of phosphorus should be limited early in the
course of renal disease to prevent the development of secondary
hyperparathyroidism and its sequelae.

Clinical Disorders of Phosphorus and
Vitamin D Metabolism
Nesbitt et al (6) presented evidence that the renal tubular reabsorption of phosphate and renal synthesis of 1,25-dihydroxyvitamin D are closely linked. Thus, TmP/GFR or tubular phosphate reabsorption and plasma 1,25-dihydroxyvitamin D varied
directiy with each other in patients with X-linked hypophosphatemic rickets, tumor-induced osteomalacia, and tumoral calcinosis. However, there was poor correlation between
TmP/GFR and plasma 1,25-dihydroxyvitamin D in patients
with hereditary hypophosphatemic rickets and hypercalciuria.
In this disorder, circulating 1,25-dihydroxyvitamin D was increased and responsible for the hypercalciuria. They suggested
that the proximal renal tubular site at which phosphate is reabsorbed may be important in the regulation of renal synthesis of
1,25-dihydroxyvitamin D and that the interrelation of these two
processes, which appear to be linked, is complex.

Abnormal Vitamin D and Calcium Metabolism
in Sarcoidosis and Related Diseases
Hypercalcemia caused by increased circulating 1,25-dihydroxyvitamin D is a potentially preventable cause of renal
failure and death in patients with sarcoidosis. Liel and colleagues (7) developed a means to identify patients who may be at
risk to develop hypercalcemia. Their method is based on the fact
that feedback regulation of circulating 1,25-dihydroxyvitamin D
normally occurs in response to increases in dietary calcium.
They found in a small number of patients with sarcoidosis and
active disease, in contrast to normal subjects in whom serum
1,25-dihydroxyvitamin D declined in response to increases in
dietary calcium, that serum 1,25-dihydroxyvitamin D did not
change. These results were interpreted to mean that since the
production of 1,25-dihydroxyvitamin D is not normally regu-
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lated, it must be synthesized at extrarenal sites in patients with
active disease. Thus, patients with active disease may be at risk
for developing hypercalcemia. In fact, one of the patients developed hypercalcemia in the course of a summer.

The Effects of Race and Body Habitus on
the Vitamin D Endocrine System
Blacks and obese subjects have a greater bone mass than
whites and nonobese individuals and are at lessriskfor developing osteoporosis and fractures of the hip (8). Blacks and obese
whites also show decreases in semm 25-hydroxyvitamin D and
urinary calcium and increases in semm 1,25-dihydroxyvitamin
D and urinary cyclic adenosine 3',5'-monopho.sphate as compared to nonobese white men and women. It remains unclear
whether the altered vitamin D endocrine system in these subjects is related to the increased bone mass.
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